Class: Fourth-generation fluoroquinolone
Indications: Bacterial conjunctivitis and acute bacterial keratitis
Dosing: 1 drop three times daily for 5 days
Key Benefit: Broad spectrum with excellent coverage against resistant strains
UK Approximate Cost: £45 per treatment (single-dose vial)
Generic Alternatives: Ciprofloxacin (~£5-£8), Tobramycin (~£12)
Cost-Effectiveness: Higher upfront cost but potentially better outcomes for resistant infections
Drug | Generation | Dosing | Cost |
---|---|---|---|
Besivance | 4th-gen fluoroquinolone | 1 drop TID × 5 days | £45 |
Ciprofloxacin | 2nd-gen fluoroquinolone | 1 drop QID × 7 days | £5-£8 |
Moxifloxacin | 4th-gen fluoroquinolone | 1 drop BID × 5 days | £30 |
Gatifloxacin | 3rd-gen fluoroquinolone | 1 drop QID × 7 days | £20 |
Tobramycin | Aminoglycoside | 1 drop QID × 7-10 days | £12 |
Polymyxin B/Trimethoprim | Combination | 1 drop QID × 7 days | £8 |
Got an eye infection and wondering whether Besivance is the right choice or if another eye drop might work better? You’re not alone. Patients and clinicians constantly weigh effectiveness, safety, dosing convenience, and cost when picking an ophthalmic antibiotic. Below you’ll find a no‑fluff rundown of Besivance, the most common alternatives, and a side‑by‑side comparison that lets you see which option fits your situation.
Besivance is a prescription ophthalmic solution that contains the fluoroquinolone antibiotic besifloxacin. It received FDA approval in 2009 and is marketed mainly for bacterial conjunctivitis and acute bacterial keratitis. The 0.6% solution comes in a single‑dose vial, eliminating the need for preservatives that can irritate sensitive eyes.
Besifloxacin belongs to the fourth‑generation fluoroquinolones. It blocks bacterial DNA gyrase and topoisomerase IV, enzymes essential for DNA replication. This dual‑target action gives it a broader and more potent spectrum than older fluoroquinolones, covering common culprits like Staphylococcus aureus, Streptococcus pneumoniae, Pseudomonas aeruginosa, and Haemophilus influenzae. Because the drug is delivered directly to the eye, systemic exposure is minimal, reducing the risk of systemic side effects.
Below are the five most frequently prescribed ophthalmic antibiotics that clinicians compare with Besivance.
Drug | Generation / Class | Typical Dosing | Gram‑Positive Coverage | Gram‑Negative Coverage | Resistance Concerns | Approx. UK Cost (per treatment) |
---|---|---|---|---|---|---|
Besivance | 4th‑gen fluoroquinolone | 1 drop TID for 5days | Excellent (MRSA‑type strains) | Excellent (incl. Pseudomonas) | Low - retains activity vs many resistant isolates | ≈£45 (single‑dose vial) |
Ciprofloxacin | 2nd‑gen fluoroquinolone | 1 drop QID for 7days | Good (not active vs MRSA) | Good (incl. Pseudomonas) | Moderate - resistance rising in Staph spp. | ≈£5-£8 (generic bottle) |
Moxifloxacin | 4th‑gen fluoroquinolone | 1 drop BID for 5days | Very good (covers resistant Staph) | Very good (incl. Pseudomonas) | Low - similar to Besivance | ≈£30 (branded) |
Gatifloxacin | 3rd‑gen fluoroquinolone | 1 drop QID for 7days | Good (some MRSA gaps) | Good (Pseudomonas) | Moderate - some regional resistance | ≈£20 (branded) |
Tobramycin | Aminoglycoside | 1 drop QID for 7‑10days | Poor (Gram‑positive limited) | Excellent (Pseudomonas) | Low - resistance rare but strain‑specific | ≈£12 (generic) |
Polymyxin B/Trimethoprim | Combination (membrane + folate) | 1 drop QID for 7days | Moderate | Moderate | Higher - emerging resistance in Gram‑negatives | ≈£8 (generic) |
Pros
Cons
Ciprofloxacin remains the go‑to for cost‑conscious patients and for infections where resistance patterns are favorable. Its twice‑daily dosing options make it a decent choice for children who struggle with frequent drops.
Moxifloxacin offers a dosing schedule of twice daily, which many find easier than three times a day. It’s priced lower than Besivance but still above generic options.
Gatifloxacin can be useful when a suspension form is preferred for patients who dislike clear solutions, though the temporary blur may be annoying.
Tobramycin shines for suspected Pseudomonas keratitis, especially after contact‑lens‑related injuries. It’s often paired with steroids for inflammation control.
Polymyxin B/Trimethoprim provides a cheaper broad‑spectrum choice but should be avoided in regions with high polymyxin resistance.
All topical fluoroquinolones, including Besivance, can cause mild burning, stinging, or transient visual blur. Serious events (e.g., tendon rupture, systemic QT prolongation) are virtually unheard of when used eye‑only because systemic absorption is negligible.
Allergies are the main reason to switch agents. If a patient develops persistent redness, swelling, or itching beyond the first 24‑48hours, they should discontinue and contact their eye‑care provider.
Contact‑lens wearers should remove lenses before applying any drops and wait at least 15minutes before reinserting to avoid drug‑lens interactions.
If you’ve been prescribed Besivance but are unsure about the regimen, follow these steps:
Most patients notice reduced redness and discharge within 2‑3days. Full resolution of bacterial conjunctivitis usually occurs by day5, which matches the treatment course.
Yes, but remove the lenses before each drop and wait at least 15minutes before putting them back. This prevents the drug from binding to the lens material and reduces irritation.
Topical use delivers minimal systemic absorption, and there are no documented adverse pregnancy outcomes. Nonetheless, it should only be used when the benefits outweigh any theoretical risk, under a doctor’s guidance.
The higher price reflects its preservative‑free single‑dose packaging, newer patent‑protected formulation, and the broader spectrum that covers resistant strains. Generic fluoroquinolones lack these specific features.
If you develop persistent burning, an allergic rash, or worsening infection after 48hours, contact your eye‑care professional. They may swap you to tobramycin (if Pseudomonas is a concern) or a different fluoroquinolone based on culture results.
Darlene Young
October 3, 2025 AT 03:43Besivance really shines when you’re battling a stubborn infection that won’t quit – its fourth‑generation fluoroquinolone backbone punches through resistant strains like a seasoned detective cracking a cold case. The preservative‑free vial means less irritation for patients prone to dry eye, and the three‑times‑daily schedule for five days is surprisingly manageable compared to the week‑long grind of older drops. While the price tag looks steep at £45, think of it as an investment in a quicker, more reliable cure rather than a cheap band‑aid that may fail. In my experience, the broad‑spectrum coverage can be a game‑changer when cultures show mixed flora. So, if you’re wrestling with a tough bacterial conjunctivitis, Besivance is worth the extra pennies.